Boothbay Fund Management’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-60,600
Closed -$1.86M 1943
2025
Q3
$1.86M Buy
+60,600
New +$1.39M 0.03% 596
2025
Q1
Sell
-72,100
Closed -$955K 1387
2024
Q4
$955K Sell
72,100
-30,500
-30% -$739K 0.02% 657
2024
Q3
$3.44M Buy
+102,600
New +$3.5M 0.08% 348
2021
Q2
Sell
-189
Closed -$407K 1828
2021
Q1
$407K Hold
189
0.02% 1047
2020
Q4
$406K Buy
+189
New +$4.59K 0.02% 833
2018
Q4
Sell
-760
Closed -$7.58M 654
2018
Q3
$7.58M Buy
+760
New +$63.1K 0.75% 28

Other funds holding ANAB

Boothbay Fund Management's ANAB Position: Q4 2025 in Review

Boothbay Fund Management sold out of AnaptysBio (ANAB) in Q4 2025, closing a stake of 27,402 shares — an estimated $839K sold.

Boothbay Fund Management first reported a position in ANAB in Q1 2019 and held it in 6 quarters. The position peaked at $1.17M in Q1 2019. 179 funds tracked by Wall St. Rank hold ANAB as of Q4 2025.

  • Boothbay Fund Management reported no remaining AnaptysBio position as of Q4 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 27,402 AnaptysBio shares in Q4 2025, an estimated $839K.
  • Boothbay Fund Management first reported a position in AnaptysBio in Q1 2019 and held it in 6 quarters.
  • Boothbay Fund Management's AnaptysBio position peaked at $1.17M in Q1 2019.
  • 179 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.